Søren Møller, Ph.D.

Dr. Søren Møller has been a member of our Board of Directors since 2020.  Dr. Møller is currently employed as a Managing Partner at Novo Holdings A/S, a Danish limited liability company that manages investments and financial assets. He joined Novo Holdings A/S in 2011 as Managing Investment Director of Novo Seeds. Prior to joining Novo Seeds, Dr. Møller served as global manager of Genomics at Novozymes. Before Novozymes, he was Chief Scientific Officer and Vice President of R&D at Exiqon A/S. During Dr. Møller’s tenure, Exiqon completed an IPO and the company was later acquired by Qiagen in 2016. Earlier in his career, Dr. Møller worked in cancer drug development as head of Lead Identification at BioImage A/S and as research scientist at Novo Nordisk A/S. Dr. Møller holds a M.Sc. from the Technical University of Denmark and a Ph.D. in molecular biology from the Technical University of Denmark. In addition, Dr. Møller has academic training as postdoctoral fellow at Stanford University School of Medicine.